Literature DB >> 28972180

Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity.

Nicolas Arbez1, Tamara Ratovitski2, Elaine Roby2, Ekaterine Chighladze2, Jacqueline C Stewart2, Mark Ren3, Xiaofang Wang2, Daniel J Lavery4, Christopher A Ross5,6,7.   

Abstract

Huntington's disease (HD) is caused in large part by a polyglutamine expansion within the huntingtin (Htt) protein. Post-translational modifications (PTMs) control and regulate many protein functions and cellular pathways, and PTMs of mutant Htt are likely important modulators of HD pathogenesis. Alterations of selected numbers of PTMs of Htt fragments have been shown to modulate Htt cellular localization and toxicity. In this study, we systematically introduced site-directed alterations in individual phosphorylation and acetylation sites in full-length Htt constructs. The effects of each of these PTM alteration constructs were tested on cell toxicity using our nuclear condensation assay and on mitochondrial viability by measuring mitochondrial potential and size. Using these functional assays in primary neurons, we identified several PTMs whose alteration can block neuronal toxicity and prevent potential loss and swelling of the mitochondria caused by mutant Htt. These PTMs included previously described sites such as serine 116 and newly found sites such as serine 2652 throughout the protein. We found that these functionally relevant sites are clustered in protease-sensitive domains throughout full-length Htt. These findings advance our understanding of the Htt PTM code and its role in HD pathogenesis. Because PTMs are catalyzed by enzymes, the toxicity-modulating Htt PTMs identified here may be promising therapeutic targets for managing HD.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Huntington disease; neurodegeneration; neuron; phosphorylation; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28972180      PMCID: PMC5702665          DOI: 10.1074/jbc.M117.782300

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

2.  Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity.

Authors:  Birgit Schilling; Juliette Gafni; Cameron Torcassi; Xin Cong; Richard H Row; Michelle A LaFevre-Bernt; Michael P Cusack; Tamara Ratovitski; Ricky Hirschhorn; Christopher A Ross; Bradford W Gibson; Lisa M Ellerby
Journal:  J Biol Chem       Date:  2006-06-16       Impact factor: 5.157

3.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

Review 4.  The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease.

Authors:  Yan Xu; Yulin Deng; Hong Qing
Journal:  J Neurochem       Date:  2015-08-03       Impact factor: 5.372

Review 5.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats.

Authors:  Tamara Ratovitski; Robert N O'Meally; Mali Jiang; Raghothama Chaerkady; Ekaterine Chighladze; Jacqueline C Stewart; Xiaofang Wang; Nicolas Arbez; Elaine Roby; Athanasios Alexandris; Wenzhen Duan; Ravi Vijayvargia; Ihn Sik Seong; Daniel J Lavery; Robert N Cole; Christopher A Ross
Journal:  J Proteome Res       Date:  2017-07-03       Impact factor: 4.466

7.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

8.  Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons.

Authors:  Emilie Colin; Diana Zala; Géraldine Liot; Hélène Rangone; Maria Borrell-Pagès; Xiao-Jiang Li; Frédéric Saudou; Sandrine Humbert
Journal:  EMBO J       Date:  2008-07-10       Impact factor: 11.598

Review 9.  Mitochondria: from cell death executioners to regulators of cell differentiation.

Authors:  Atsuko Kasahara; Luca Scorrano
Journal:  Trends Cell Biol       Date:  2014-09-02       Impact factor: 20.808

10.  Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity.

Authors:  Erin E Watkin; Nicolas Arbez; Elaine Waldron-Roby; Robert O'Meally; Tamara Ratovitski; Robert N Cole; Christopher A Ross
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

View more
  17 in total

1.  Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.

Authors:  Chelsy R Eddings; Nicolas Arbez; Sergey Akimov; Michal Geva; Michael R Hayden; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2019-05-17       Impact factor: 5.996

2.  Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.

Authors:  Joel D Federspiel; Todd M Greco; Krystal K Lum; Ileana M Cristea
Journal:  Mol Cell Proteomics       Date:  2019-04-30       Impact factor: 5.911

3.  N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation.

Authors:  Laura E Bowie; Tamara Maiuri; Melanie Alpaugh; Michelle Gabriel; Nicolas Arbez; Danny Galleguillos; Claudia L K Hung; Shreya Patel; Jianrun Xia; Nicholas T Hertz; Christopher A Ross; David W Litchfield; Simonetta Sipione; Ray Truant
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

4.  Neuroprotective Effects of σ2R/TMEM97 Receptor Modulators in the Neuronal Model of Huntington's Disease.

Authors:  Jing Jin; Nicolas Arbez; James J Sahn; Yan Lu; Kathryn T Linkens; Timothy R Hodges; Anthony Tang; Robyn Wiseman; Stephen F Martin; Christopher A Ross
Journal:  ACS Chem Neurosci       Date:  2022-09-15       Impact factor: 5.780

5.  Interaction of huntingtin with PRMTs and its subsequent arginine methylation affects HTT solubility, phase transition behavior and neuronal toxicity.

Authors:  Tamara Ratovitski; Mali Jiang; Robert N O'Meally; Priyanka Rauniyar; Ekaterine Chighladze; Anikó Faragó; Siddhi V Kamath; Jing Jin; Alexey V Shevelkin; Robert N Cole; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2022-05-19       Impact factor: 5.121

6.  Huntingtin-mediated axonal transport requires arginine methylation by PRMT6.

Authors:  Alice Migazzi; Chiara Scaramuzzino; Eric N Anderson; Debasmita Tripathy; Ivó H Hernández; Rogan A Grant; Michela Roccuzzo; Laura Tosatto; Amandine Virlogeux; Chiara Zuccato; Andrea Caricasole; Tamara Ratovitski; Christopher A Ross; Udai B Pandey; José J Lucas; Frédéric Saudou; Maria Pennuto; Manuela Basso
Journal:  Cell Rep       Date:  2021-04-13       Impact factor: 9.423

7.  Inhibition of Crmp1 Phosphorylation at Ser522 Ameliorates Motor Function and Neuronal Pathology in Amyotrophic Lateral Sclerosis Model Mice.

Authors:  Tetsuya Asano; Haruko Nakamura; Yuko Kawamoto; Mikiko Tada; Yayoi Kimura; Hiroshi Takano; Ryoji Yao; Hiroya Saito; Takuya Ikeda; Hiroyasu Komiya; Shun Kubota; Shunta Hashiguchi; Keita Takahashi; Misako Kunii; Kenichi Tanaka; Yoshio Goshima; Fumio Nakamura; Hideyuki Takeuchi; Hiroshi Doi; Fumiaki Tanaka
Journal:  eNeuro       Date:  2022-05-23

Review 8.  Strategies to Investigate Ubiquitination in Huntington's Disease.

Authors:  Karen A Sap; Eric A Reits
Journal:  Front Chem       Date:  2020-06-11       Impact factor: 5.221

9.  Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics.

Authors:  Sergey S Akimov; Mali Jiang; Amanda J Kedaigle; Nicolas Arbez; Leonard O Marque; Chelsy R Eddings; Paul T Ranum; Emma Whelan; Anthony Tang; Ronald Wang; Lauren R DeVine; Conover C Talbot; Robert N Cole; Tamara Ratovitski; Beverly L Davidson; Ernest Fraenkel; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2021-11-30       Impact factor: 5.121

Review 10.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.